恩格列净治疗与心力衰竭患者白蛋白尿水平的关联:EMPEROR-Pooled二次分析
该研究为EMPEROR-Reduced和EMPEROR-Preserved试验的post hoc汇总分析,纳入9673例心力衰竭患者,按基线尿白蛋白/肌酐比值(UACR)分层。结果显示恩格列净降低新发大量白蛋白尿风险(HR 0.81;95%CI 0.70-0.94;95%CI 1.07-1.59;
要点
- 恩格列净在各基线白蛋白尿水平的心衰患者中均一致降低心血管死亡或心衰住院风险。
- 恩格列净减少新发大量白蛋白尿并促进白蛋白尿逆转,但总体人群UACR未显著降低。
核心结论
- 与安慰剂相比,恩格列净降低心衰患者心血管死亡或心衰住院风险,且不受基线白蛋白尿水平影响。
- 恩格列净减少新发大量白蛋白尿并增加白蛋白尿逆转,但总体人群UACR未显著降低。
研究设计与样本
- EMPEROR-Reduced和EMPEROR-Preserved试验的post hoc汇总分析,纳入9673例心力衰竭患者。
- 随机分配至恩格列净或安慰剂,排除缺失基线UACR数据者。
关键数值与推荐
- 正常白蛋白尿定义为UACR<30 mg/g,大量白蛋白尿定义为UACR>300 mg/g。
临床怎么用
- 恩格列净的心衰获益不受基线白蛋白尿水平影响,各UACR类别均可考虑使用。
- 恩格列净可减少新发大量白蛋白尿并促进白蛋白尿逆转,对糖尿病合并心衰患者可能额外改善UACR。
局限性
- 为post hoc二次分析,存在残余混杂可能。
- 排除了缺失基线UACR数据的患者,可能引入选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Albuminuria, routinely assessed as spot urine albumin-to-creatinine ratio (UACR), indicates structural damage of the glomerular filtration barrier and is associated with poor kidney and cardiovascular outcomes. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce UACR in patients with type 2 diabetes, but its use in patients with heart failure (HF) is less well studied. OBJECTIVE: To analyze the association of empagliflozin with study outcomes across baseline levels of albuminuria and change in albuminuria in patients with HF across a wide range of ejection fraction levels. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis included all patients with HF from the EMPEROR-Pooled analysis using combined individual patient data from the international multicenter randomized double-blind parallel-group, placebo-controlled EMPEROR-Reduced and EMPEROR-Preserved trials. Participants in the original trials were excluded from this analysis if they were missing baseline UACR data. EMPEROR-Preserved was conducted from March 27, 2017, to April 26, 2021, and EMPEROR-Reduced was conducted from April 6, 2017, to May 28, 2020. Data were analyzed from January to June 2022. INTERVENTIONS: Randomization to empagliflozin or placebo. MAIN OUTCOMES AND MEASURES: New-onset macroalbuminuria and regression to normoalbuminuria and microalbuminuria. RESULTS: A total of 9673 patients were included (mean [SD] age, 69.9 [10.4] years; 3551 [36.7%] female and 6122 [63.3%] male). Of these, 5552 patients had normoalbuminuria (UACR <30 mg/g) and 1025 had macroalbuminuria (UACR >300 mg/g). Compared with normoalbuminuria, macroalbuminuria was associated with younger age, races other than White, obesity, male sex, site region other than Europe, higher levels of N-terminal pro-hormone brain natriuretic peptide and high-sensitivity troponin T, higher blood pressure, higher New York Heart Association class, greater HF duration, more frequent previous HF hospitalizations, diabetes, hypertension, lower eGFR, and less frequent use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and mineralocorticoid receptor antagonists. An increase in events was observed in individuals with higher UACR levels. The association of empagliflozin with cardiovascular mortality or HF hospitalization was consistent across UACR categories (hazard ratio [HR], 0.80; 95% CI, 0.69-0.92 for normoalbuminuria; HR, 0.74; 95% CI, 0.63-0.86 for microalbuminuria; HR, 0.78; 95% CI, 0.63-0.98 for macroalbuminuria; interaction P trend = .71). Treatment with empagliflozin was associated with lower incidence of new macroalbuminuria (HR, 0.81; 95% CI, 0.70-0.94; P = .005) and an increase in rate of remission to sustained normoalbuminuria or microalbuminuria (HR, 1.31; 95% CI, 1.07-1.59; P = .009) but not with a reduction in UACR in the overall population; however, UACR was reduced in patients with diabetes, who had higher UACR levels than patients without diabetes (geometric mean for diabetes at baseline, 0.91; 95% CI, 0.85-0.98 and for no diabetes at baseline, 1.08; 95% CI, 1.01-1.16; interaction P = .008). CONCLUSIONS AND RELEVANCE: In this post hoc analysis of a randomized clinical trial, compared with placebo, empagliflozin was associated with reduced HF hospitalizations or cardiovascular death irrespective of albuminuria levels at baseline, reduced progression to macroalbuminuria, and reversion of macroalbuminuria. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03057977 and NCT03057951.
引用
- Ferreira, Zannad, Butler, et al. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled. JAMA Cardiol. 2022. PMID: 36129693. doi:10.1001/jamacardio.2022.2924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。